Crowdsourcing to Optimize Trial Design in Metformin for Prostate Cancer Study
Transparency Life Sciences, LLC, and Dr. Matthew Galsky, Associate Professor of Medicine, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, have collaborated to design and conduct a pilot trial assessing metformin as a potential treatment for prostate cancer.
Related article:The First FDA-Approved Crowdsourced Protocol: An Interview with Tomasz Sablinski, MD, PhD
Transparency Life Sciences, LLC (TLS), and Dr. Matthew Galsky, Associate Professor of Medicine, Division of Hematology/Oncology at the Icahn School of Medicine at Mount Sinai, have collaborated to design and conduct a pilot trial assessing metformin as a potential treatment for prostate cancer. Metformin, widely prescribed for diabetes, has shown promising activity against prostate and other cancers in preclinical and clinical studies.
In a statement, Dr. Galsky said, "One goal of this pilot study is to obtain a preliminary assessment of whether metformin can affect rising prostate specific antigen (PSA) levels in men who have been treated for localized prostate cancer. A second goal is to test whether it is feasible to conduct a cancer trial that incorporates crowdsourcing into the study design and uses telemonitoring to eliminate most patient site visits. Our prior research demonstrates that cancer trials are highly inefficient and geographically inaccessible to a large proportion of cancer patients. We are optimistic that a greater number of patients would participate if they were more engaged in the process and the burden of site visits were reduced."
To that end, the study will use TLS Protocol Builder, its online crowdsourcing tool that elicits input from patients, physicians and researchers to help design clinical trials. It will also add the telemonitoring aspect through TLS' tele health partner AMC Health in the metformin study.
You can read the full release here.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
